Jul 21, 2026 04:30PM
May 21, 2026 07:30AM
May 15, 2026 04:00PM
May 13, 2026 04:10PM
May 13, 2026 04:10PM
Apr 17, 2026 04:00PM
Apr 17, 2026 04:00PM Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Develo
Apr 15, 2026 04:05PM
Mar 19, 2026 07:21AM
Mar 17, 2026 05:54PM
Mar 2, 2026 03:39PM
Feb 24, 2026 08:00AM
Feb 23, 2026 08:00AM
Feb 18, 2026 08:00AM Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory
Feb 17, 2026 10:48AM
Jan 23, 2026 08:13AM
Jan 23, 2026 08:11AM
Jan 8, 2026 07:32AM
Jan 8, 2026 07:30AM
Jan 6, 2026 07:30AM
Jan 6, 2026 07:30AM Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates v
Dec 17, 2025 09:34AM
Dec 17, 2025 09:34AM
Dec 17, 2025 07:30AM
Dec 17, 2025 07:30AM
Nov 13, 2025 04:10PM
Oct 22, 2025 04:27PM
Oct 22, 2025 04:15PM Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC Internation
Oct 1, 2025 04:30PM
Aug 13, 2025 04:15PM
May 15, 2025 07:26AM
May 14, 2025 04:10PM
Apr 25, 2025 08:00AM
Apr 7, 2025 04:05PM
Apr 7, 2025 04:05PM Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer
Mar 27, 2025 05:44PM
Mar 19, 2025 08:00AM
Mar 19, 2025 08:00AM
Feb 5, 2025 08:00AM
Feb 5, 2025 08:00AM
Nov 13, 2024 07:00AM
Oct 17, 2024 08:00AM Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization Wo
Oct 16, 2024 04:00PM
Oct 11, 2024 08:03AM
Oct 11, 2024 08:00AM
Sep 16, 2024 06:46AM
Sep 14, 2024 03:10AM
Sep 10, 2024 08:00AM
Sep 9, 2024 07:00AM Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316
Aug 13, 2024 08:00AM

326,431 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All